Admilparant
AssetAlso BMS-986278
Blocks lysophosphatidic acid receptor 1 signaling to reduce fibrosis.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Inflammation
- 4
- Indications
- 2
- Trials
- 2
- Developers
Indications
4Idiopathic pulmonary fibrosis
Phase 3, businesswire.com, 12 Oct 2026
Progressive pulmonary fibrosis
Phase 3, Active not recruiting, NCT06025578, clinicaltrials.gov, 7 Oct 2026
Pulmonary fibrosis
Phase 3, endpoints.news, 12 Oct 2026
1 more
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials2
- Evidence for its targets3
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.